Literature DB >> 31258071

Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines.

Maria L Guevara1, Stefano Persano2, Francesca Persano3.   

Abstract

Cancer vaccines have been widely explored as a key tool for effective cancer immunotherapy. Despite a convincing rationale behind cancer vaccines, extensive past efforts were unsuccessful in mediating significantly relevant anti-tumor activity in clinical studies. One of the major reasons for such poor outcome, among others, is the low immunogenicity of more traditional vaccines, such as peptide-, protein- and DNA- based vaccines. Recently, mRNA emerged as a promising alternative to traditional vaccine strategies due to its high immunogenicity, suitability for large-scale and low-cost production, and superior safety profile. However, the clinical application of mRNA-based anti-cancer vaccines has been limited by their instability and inefficient in vivo delivery. Recent technological advances have now largely overcome these issues and lipid-based vectors have demonstrated encouraging results as mRNA vaccine platforms against several types of cancers. This review intends to provide a detailed overview of lipid-based vectors for the development of therapeutic mRNA-based anti-tumor vaccines. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cancer; immunotherapy; liposome; mRNA; nanoparticles; non-viral vectors; vaccines.

Mesh:

Substances:

Year:  2019        PMID: 31258071     DOI: 10.2174/1381612825666190619150221

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  15 in total

Review 1.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

Review 2.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

3.  Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy.

Authors:  Rebuma Firdessa-Fite; Rémi J Creusot
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-11       Impact factor: 5.849

Review 4.  Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?

Authors:  Alfredo Parra-Lucares; Luis Toro; Sebastián Weitz-Muñoz; Cristóbal Ramos
Journal:  Viruses       Date:  2021-12-13       Impact factor: 5.048

Review 5.  Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity.

Authors:  Stefano Persano; Pradip Das; Teresa Pellegrino
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 6.  Nano-Microparticle Platforms in Developing Next-Generation Vaccines.

Authors:  Giuseppe Cappellano; Hugo Abreu; Chiara Casale; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Vaccines (Basel)       Date:  2021-06-05

Review 7.  Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors.

Authors:  Yoshie Kametani; Yusuke Ohno; Shino Ohshima; Banri Tsuda; Atsushi Yasuda; Toshiro Seki; Ryoji Ito; Yutaka Tokuda
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

Review 8.  Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy.

Authors:  Maria L Guevara; Francesca Persano; Stefano Persano
Journal:  Front Chem       Date:  2020-10-23       Impact factor: 5.221

9.  Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.

Authors:  Nidhi Chauhan; Shringika Soni; Abhinandan Gupta; Mohammad Aslam; Utkarsh Jain
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

Review 10.  Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles.

Authors:  Christophe Delehedde; Luc Even; Patrick Midoux; Chantal Pichon; Federico Perche
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.